These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 15308367)

  • 41. Progress in the control of measles in Ghana, 1980-2000.
    Bosu WK; Essel-Ahun M; Adjei S; Strebel P
    J Infect Dis; 2003 May; 187 Suppl 1():S44-50. PubMed ID: 12721890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Global eradication of measles: an epidemiologic and economic evaluation.
    Levin A; Burgess C; Garrison LP; Bauch C; Babigumira J; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S98-106. PubMed ID: 21666220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Epidemiological study and cost evaluation of measles in Lyons hospitals over a 5-year period].
    Loras-Duclaux I; David L; Peyramond D; Floret D; Lachaux A; Hermier M
    Pediatrie; 1988; 43(5):451-4. PubMed ID: 3200658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measles control in Sub-Saharan Africa: South Africa as a case study.
    Verguet S; Jassat W; Hedberg C; Tollman S; Jamison DT; Hofman KJ
    Vaccine; 2012 Feb; 30(9):1594-600. PubMed ID: 22230581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
    Yekta Z; Pourali R; Taravati MR; Shahabi S; Salary S; Khalily F; Farzin A
    East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys.
    Nigatu W; Samuel D; Cohen B; Cumberland P; Lemma E; Brown DW; Nokes J
    Vaccine; 2008 Sep; 26(37):4769-74. PubMed ID: 18644417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population-wide benefits of routine vaccination of children against influenza.
    Weycker D; Edelsberg J; Halloran ME; Longini IM; Nizam A; Ciuryla V; Oster G
    Vaccine; 2005 Jan; 23(10):1284-93. PubMed ID: 15652671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mass measles control in West and Central Africa.
    Foster SO; Pifer JM
    Afr J Med Sci; 1971 Apr; 2(2):151-8. PubMed ID: 5111614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues.
    Pless RP; Bentsi-Enchill AD; Duclos P
    J Infect Dis; 2003 May; 187 Suppl 1():S291-8. PubMed ID: 12721928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of administrative data to estimate mass vaccination campaign coverage, Burkina Faso, 1999.
    Zuber PL; Yaméogo KR; Yaméogo A; Otten MW
    J Infect Dis; 2003 May; 187 Suppl 1():S86-90. PubMed ID: 12721897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the measles-rubella mass vaccination campaign in the population covered by Tehran University of Medical Sciences.
    Majdzadeh R; Moradi A; Zeraati H; Sepanlou SG; Zamani G; Zonobi V
    East Mediterr Health J; 2008; 14(4):810-7. PubMed ID: 19166164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of a measles immunisation campaign on measles admissions to a Natal hospital.
    Abdool Karim SS; Abdool Karim Q; Chamane M
    S Afr Med J; 1991 Dec; 80(11-12):579-81. PubMed ID: 1745947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Are measles and mumps vaccinations worth while in Switzerland?].
    Just M
    Schweiz Med Wochenschr; 1978 Nov; 108(45):1763-8. PubMed ID: 100878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
    Babigumira JB; Levin A; Burgess C; Garrison LP; Bauch CT; Braka F; Mbabazi WB; Nabyonga JO; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S116-23. PubMed ID: 21666152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of measles outbreak response vaccination campaign in Dar es Salaam, Tanzania.
    Goodson JL; Wiesen E; Perry RT; Mach O; Kitambi M; Kibona M; Luman ET; Cairns KL
    Vaccine; 2009 Sep; 27(42):5870-4. PubMed ID: 19656496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Costs and benefits of measles vaccination].
    Ambrosch F; Wiedermann G; Harasek G
    Fortschr Med; 1978 Feb; 96(8):409-14. PubMed ID: 415953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measles eradication in the Americas: progress to date.
    de Quadros CA; Izurieta H; Venczel L; Carrasco P
    J Infect Dis; 2004 May; 189 Suppl 1():S227-35. PubMed ID: 15106116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measles outbreak in an asylum-seekers' shelter in Germany: comparison of the implemented with a hypothetical containment strategy.
    Takla A; Barth A; Siedler A; Stöcker P; Wichmann O; Deleré Y
    Epidemiol Infect; 2012 Sep; 140(9):1589-98. PubMed ID: 22313789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
    Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
    Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts.
    Costa A; Henao-Restrepo AM; Marie Hall S; Jarrett S; Hoekstra EJ
    J Infect Dis; 2003 May; 187 Suppl 1():S22-8. PubMed ID: 12721888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.